.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Julphar
Mallinckrodt
US Army
McKesson
QuintilesIMS
Express Scripts
Accenture
Harvard Business School

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 016273

« Back to Dashboard
NDA 016273 describes LASIX, which is a drug marketed by Sanofi Aventis Us and Us Pharm Holdings and is included in three NDAs. It is available from two suppliers. Additional details are available on the LASIX profile page.

The generic ingredient in LASIX is furosemide. There are twenty-one drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the furosemide profile page.

Summary for 016273

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 016273

Medical Subject Heading (MeSH) Categories for 016273

Suppliers and Packaging for NDA: 016273

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LASIX
furosemide
TABLET;ORAL 016273 NDA Sanofi-Aventis U.S. LLC 0039-0060 0039-0060-13 100 TABLET in 1 BOTTLE (0039-0060-13)
LASIX
furosemide
TABLET;ORAL 016273 NDA Sanofi-Aventis U.S. LLC 0039-0060 0039-0060-50 500 TABLET in 1 BOTTLE (0039-0060-50)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength40MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength20MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength80MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 016273

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Pharm Holdings
LASIX
furosemide
TABLET;ORAL016273-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
LASIX
furosemide
TABLET;ORAL016273-003Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Us Pharm Holdings
LASIX
furosemide
TABLET;ORAL016273-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Argus Health
US Department of Justice
Farmers Insurance
UBS
Medtronic
Julphar
Merck
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot